First Study to Track Individual Collagen Peptides Through the Body Reveals Surprisingly Low Absorption

First individual PK profiling of collagen peptides shows Gly-Pro-Hyp has 4.4% oral bioavailability and Pro-Hyp has 19.3%, with flip-flop kinetics indicating transporter-mediated absorption and double-peak patterns suggesting multiple absorption sites.

Rats received individual collagen peptides (Gly-Pro-Hyp, Pro-Hyp, Gly-Pro) via IV (5 mg/kg) and intragastric (100 mg/kg) routes. Plasma levels and urinary excretion were measured by LC-MS/MS. Pharmacokinetic parameters including absolute oral bioavailability, Cmax, Tmax, and elimination rates were calculated.

Millions of people take collagen supplements, but the fundamental question of how much actually reaches the bloodstream was unanswered until now. This study provides the first rigorous pharmacokinetic data for individual collagen peptides, showing that absorption is low and peptide-specific — information essential for rational dosing.

The collagen supplement market is worth billions, but scientific understanding of what these products actually do in the body is still catching up. This PK study provides critical baseline data: even the best-absorbed collagen peptide (Pro-Hyp) has less than 20% bioavailability, meaning most of what you swallow never reaches the bloodstream. This information should guide supplement dosing, formulation development, and help explain why clinical trial results for collagen supplements have been mixed.

Rat pharmacokinetics — human absorption may differ significantly due to differences in gut transporters, pH, and transit time. Individual peptides were given in isolation, while collagen supplements contain complex mixtures where peptides may compete for transporters. The doses used (100 mg/kg oral) are high relative to typical human supplement doses. The biological significance of the small absorbed fraction is not addressed.